TABLE 2.

Longitudinal Changes in the Markers of CVD-RFs

	Baseline		6 mo		12 mo		24 mo		36 mo
	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)
EBP	238	43.6 (36.3–51.3)	206	20.2 (14.7–27.1)	213	16.8 (11.9–23.2)	198	10.9 (7.0–16.5)	190	15.5 (10.6–22.0)
IFG	234	26.0 (19.9–33.1)	190	5.2 (2.7–9.7)	202	4.3 (2.2–8.3)	191	4.1 (2.0–8.2)	181	3.9 (1.8–8.1)
Diabetes	239	12.6 (8.2–18.7)	200	5.9 (3.2–10.9)	206	1.9 (0.7–5.3)	193	1.8 (0.6–5.2)	187	0.6 (0.1–3.8)
Dyslipidemia	238	75.2 (68.7–80.8)	204	53.1 (45.4–60.7)	210	26.8 (20.7–33.8)	196	25.8 (19.6–33.0)	184	29.4 (22.6–37.3)
LDL-C ≥130 mg/dL	238	7.9 (4.7–13.1)	204	6.9 (3.8–12.2)	210	5.3 (2.8–10.0)	197	5.0 (2.5–9.7)	186	4.2 (2.0–8.8)
HDL-C <40 mg/dL	238	63.5 (56.2–70.3)	204	42.4 (34.8–50.4)	210	18.7 (13.6–25.2)	197	14.1 (9.6–20.2)	186	15.2 (10.4–21.6)
Triglycerides ≥130 mg/dL	238	40.6 (33.5–48.2)	204	14.2 (9.7–20.3)	210	6.8 (4.0–11.3)	197	12.5 (8.3–18.4)	186	11.4 (7.3–17.4)
Abnormal triglyceride–to–HDL-C ratio	226	53.7 (45.9–61.3)	195	23.7 (17.5–31.1)	201	9.8 (6.2–15.2)	188	11.0 (7.1–16.9)	175	13.3 (8.7–19.8)
Elevated HOMA-IRa	209	75.8 (68.9–81.5)	191	26.2 (20.0–33.6)	206	21.1 (15.6–27.7)	191	18.5 (13.3–25.2)	185	25.0 (18.8–32.4)
Insulin >17.0 U/mL	230	73.8 (67.1–79.5)	196	29.9 (23.3–37.3)	206	16.9 (12.1–23.0)	189	14.9 (10.3–21.1)	185	20.6 (15.0–27.5)
HbA1c ≥6.5%	231	5.9 (2.9–11.8)	199	1.9 (0.6–5.8)	206	1.8 (0.6–5.6)	193	2.1 (0.7–6.1)	191	1.2 (0.3–4.7)
hs-CRP ≥0.3 mg/dL	238	75.1 (68.4–80.8)	203	42.6 (34.9–50.6)	210	29.5 (23.0–37.0)	195	23.6 (17.6–30.8)	187	25.1 (18.8–32.8)

Changes in the prevalence (CI) of multiple CVD-RF variables determined at baseline (preoperative) and the 6-, 12-, 24-, and 36-mo time points.